Abstract The present work describes the development of a robust and sensitive targeted analysis platform for the simultaneous quantification in blood plasma of lipid oxygenated mediators and fatty acids using solid-phase extraction (SPE) and high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC-MS/MS). The concurrent analysis of these lipid mediators is challenging because of their instability, differences in solubility, and the frequent occurrence of isobaric forms with similar fragmentation patterns. Results demonstrated that the reduction of SPE temperature to 4°C is a critical parameter for preserving the hydroperoxy derivatives. Polymeric HLB cartridges increased 40-50 % ARA, EPA, and DHA sensitivity compared to C18 sorbent and also provided higher global performance for most hydroxides and other oxidation products. The proposed method for the two tested mass analyzers yields high sensitivity, good linearity, and reproducibility, with detection limits ranging 0.002-7 ng/mL and global recoveries as high as 85-112 %. However, the additional advantage of the linear ion trap (LIT) mass analyzer working in full scan product ion mode, compared to the triple quadrupole (QqQ) operating in multiple reaction monitoring (MRM), should be noted: the full scan product ion mode provides the full fragmentation spectra of compounds that allowed the discrimination of coeluting isomers and false positive identifications without additional chromatography development. The proposed lipidomic procedure demonstrates a confident, simple, and sensitive method to profile in plasma a wide range of lipid eicosanoid and docosanoid mediators, including innovatively the analysis of hydroperoxy congeners and nonoxidized PUFA precursors.
Introduction
Polyunsaturated fatty acids (PUFAs) exhibit a range of biological effects, many of which are mediated by the formation of lipid derivatives. Such metabolites are produced in vivo through the action of cyclooxygenases (COXs), lipooxygenases (LOXs), cytochrome P450 monooxygenases (CYP450), and/or free radical oxidation mechanisms [1] . PUFAs with 20 carbons like arachidonic acid (ARA) and eicosapentaenoic acid (EPA) are precursors of many eicosanoids like prostanoids (prostaglandins and thromboxanes) and leukotrienes, a family of compounds involved in inflammatory processes [2] . From ARA, series-2 prostanoids like PGE 2 , PGD 2 , or TXB 2 and series-4 leukotrienes like LTB 4 and also hydroxyeicosatetraenoic acids (HETEs) are generated by the activity of COXs and LOXs [3] , while CYP450 and autoxidation reactions result in various hydroxy-, hydroperoxy-, and epoxy-fatty acids and F 2 -isoprostanes [4] . In a similar manner, many lipid compounds are derived from EPA including series-3 prostanoids (e.g., PGE 3 , PGD 3 and TXB 3 ), series-5 leukotrienes (e.g., LTB 5 ), and hydroxy-and hydroperoxyeicosapentaenoic acids (HEPEs and HpEPEs) [5, 6] . Also derived from EPA are F 3 
-isoprostanes (a group of analgesic
Electronic supplementary material The online version of this article (doi:10.1007/s00216-014-7701-3) contains supplementary material, which is available to authorized users. compounds) [2, 7] and series-E resolvins (e.g., RvE 1 and RvE 2 ) which are a newly discovered family of trihydroxy congeners that result from COX-2 activity and act as antiinflammatory mediators [3, 8] .
Enzymatic oxidation or autoxidation of docosahexaenoic acid (DHA) produces hydroxy-docosahexaenoic acids (HDoHEs) and hydroperoxy-docosahexaenoic acids (HpDoHEs); moreover, it has been recently shown that DHA gives rise to a novel family of strong antiinflammatory compounds termed neuroprostanes with dihydroxy (protectins, PD) and trihydroxy (series-D resolvins) structures [3, 8] (Fig. S1 , Electronic Supplementary Material shows similar formation cascades of ARA, EPA, and DHA fatty acids).
Oxygenated metabolites of PUFAs have an important role in a wide range of biological functions. They are part of membrane cells, activate gene transcription, and are also involved in many diseases and inflammatory processes [9, 10] . Therefore, these lipid mediators have been investigated in the discovery of biomarkers and drug development studies [3] . Specific examples include the proinflammatory role of ARA eicosanoid and isoprostane metabolites in many processes related to oxidative stress, such as hypercholesterolemia [11] , liver cirrhosis [12] , Crest syndrome [13] , myocardial reperfusion [14] , or type 2 diabetes [15, 16] . On the other hand, many hydroxy-derived compounds of EPA and DHA are involved in the regulation of vascular tone [17] , arteriosclerosis [18] , or Alzheimer [19] and are considered markers of lipid peroxidation. Finally, novel studies have related antiinflammatory and cellular protective activities of RvE 1 , RvD 1 , and PD 1 [20] to benefits in cardiovascular diseases, dry eyes, or even Alzheimer [21, 22] .
The analytical determination of oxygenated PUFA metabolites is a challenging task, mainly because of their low physiological levels and large number of isomers with very similar physicochemical properties [10] . Therefore, a sensitive and selective detection procedure following an effective separation step is essential to comprehensively study this class of lipids [23] . Methods used for the determination of these lipid mediators currently involve an extraction and/or preconcentration step followed by chromatographic separation and mass spectrometry determination. The most common solid-phase extraction (SPE) sorbents are C18 conventional cartridges [16, 24, 25] and polymeric sorbents like Oasis-HLB [26] [27] [28] or Strata-X [29, 30] . For many years, gas chromatography coupled to mass spectrometry (GC/MS) was the method of choice for eicosanoid analysis [15, 17, 31] . Nowadays, the widespread liquid chromatography/mass spectrometry (LC-MS) coupled with high-sensitivity electrospray ionization (ESI) has provided a new approach for quantification, minimizing sample preparation requirements and particularly avoiding derivatization reactions [3, 24, 25, 32, 33] . The triple quadrupole (QqQ) mass spectrometer working in the multiple reaction monitoring (MRM) mode [16, 26, [28] [29] [30] , together with hybrid variants such as quadrupole ion trap (Q-Trap) [27, 34] and quadrupole time-of-flight (Q-TOF) [35, 36] , has become the MS technology of choice for the analysis of oxygenated PUFA metabolites.
The aim of this research was to develop an analytical methodology based on SPE and LC-MS, to allow the simultaneous detection and quantification of a wide range of lipid mediators in plasma. PUFA derivatives like prostaglandins, leukotrienes, thromboxanes, hydroxy and hydroperoxy acids, isoprostanes, resolvins, and protectins derived from ARA, EPA, and DHA and their fatty acid precursors were the target analytes. The proposed method innovatively attempts to analyze PUFA metabolites with a wide range of polarity (octanolwater partition coefficients ranged from 1.1 of PGD 3 to 7.3 of DHA), concentration (up to 4 orders of magnitude), and stability diversity (hydroperoxides are highly unstable) and applies polymeric HLB cartridges for the extraction of hydroxy and hydroperoxy PUFA congeners. Two different mass spectrometers were tested in order to discuss and compare both acquisition modes in terms of false positive identifications: a QqQ operating in the MRM mode that is commonly applied to lipidomic approaches and a linear ion trap (LIT) working in full scan product ion mode. Their analytical parameters for optimal sensitivity and selectivity were addressed. Applicability of the analytical platform was validated by analyzing plasma samples of genetically obese spontaneously hypertensive rats.
Experimental
Standards, solvents, and sorbents Thromboxane B 3 (TXB 3 , 9α-(±)11,15(S)-trihydroxythromba-5Z,13E,17Z-trien-1-oic acid), prostaglandin D 3 (PGD 3 , 9α-15(S)-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid), prostaglandin E 3 (PGE 3 , 11α-15(S)-dihydroxy-9-oxo-prosta-5Z,13E,17Z-trien-1-oic acid), prostaglandin E 2 (PGE 2 , 11α-15(S)-dihydroxy-9-oxo-prosta-5Z,13E-dien-1-oic acid), resolvin D 1 (RvD 1 , 7(S),8(R),17(S)-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid), protectin D 1 (PD 1 , 10(S),17(S)-dihydroxy-4Z,7Z,11E,13Z,15-E,19Z-docosahexaenoic acid), leukotriene B 4 (LTB 4 , 5(S),12(R)-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid), isoprostane F 2α (8isoPGF 2α , 9α,11α,15(S)-trihydroxy-8β-prosta-5Z,13E-dien-1-oic acid), isoprostane F 3α (8isoPGF 3α , 9α,11α,15(S)-trihydroxy-8β-prosta-5Z,13E,17Z-trien-1-oic acid), 15HpEPE (15(S)-hydroperoxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12HpEPE (12(S)-hydroperoxy-5Z-,8Z,10E,14Z,17Z-eicosapentaenoic acid), 17HpDoHE ( 1 7 ( S ) -h y d r o p e r o x y -4 Z , 7 Z , 1 0 Z , 1 3 Z , 1 5 E , 1 9 Zdocosahexaenoic acid), 15HEPE (±15-hydroxy-5Z,8Z,11Z,13E,17Z-eicosapentaenoic acid), 12HEPE (±12-hydroxy-5Z,8Z,10E,14Z,17Z-eicosapentaenoic acid), 5HEPE (±5-hydroxy-6E,8Z,11Z,14Z,17Z-eicosapentaenoic acid), 11HETE (±11-hydroxy-5Z,8Z,12E,14Z-eicosatetraenoic acid), 12HETE-d 8 Stock standard solutions of all analytes were prepared in ethanol and stored at −80°C under nitrogen. Individual stocks (5 μg/mL) were used to optimize ESI ionization and MS/MS fragmentation conditions by flow injection analysis.
For most species, calibration standard solutions were prepared in the range between 1 and 500 ng/mL. Two additional calibration solutions (1,000 and 1,500 ng/mL) were made for 12HEPE. A second series of calibration standards from 100 to 50,000 ng/mL was prepared for parent PUFAs (EPA, ARA, DHA) due to their higher concentration in plasma samples. The internal standard (11HETE-d 8 ) was included in all calibration solutions at a constant level of 500 ng/mL. Calibration lines were calculated by the least-squares linear regression method with the internal standard correction.
Methanol, Optima LC-MS grade, was purchased from Fisher Scientific (NJ, USA); ultrapure water was obtained from a Milli-Q system (Millipore, Bedford, MA, USA); methyl formate was purchased from Sigma Aldrich (Poole, UK); nhexane was provided by Merk (Darmstadt, Germany); and ethanol, formic acid, and hydrochloric acid were from AnalR Normapur (Fontenai, France). SPE cartridges (C18-SepPak, 100 mg, 1 mL and Oasis-HLB, 60 mg, 3 mL) were supplied by Waters (Milford, MA, USA).
Samples and sample preparation
Plasma samples were collected from female SHROB (genetically obese spontaneously hypertensive) rats, an animal model of metabolic syndrome. Animals were kept in an isolated room with a constantly regulated temperature (22±2°C) and humidity (50±10 %) in a 12-h artificial light cycle and fed ad libitum with water and a standard pelleted chow diet A04 from Harlan Ibérica (Barcelona, Spain), which contained on wet basis 60 % carbohydrate, 16 % protein, and 3 % fat. Rats were sacrificed by exsanguination, and blood was collected in tubes with ethylenediaminetetraacetic acid (EDTA) to obtain plasma (as described below). All the procedures performed agreed with the national and institutional guidelines of the Animal Care and Use Committee at the CSIC.
Blood was centrifuged at 850g (4°C, 15 min) in the presence of EDTA to remove erythrocytes. Then, plasma was supplemented with 5 mM phenylmethylsulfonyl fluoride (PMSF, protease inhibitor), and erythrocyte-free samples were immediately stored at −80°C until use. A pretreatment step for small fluids was applied to plasma samples before the SPE [37] . The defrosting process was carried out slowly in darkness, to prevent possible oxidation and degradation of analytes. Samples (90 μL) were diluted with cold methanol 30 % (v/v) to a final volume of 1 mL and spiked with the internal standard (IS) 11HETE-d 8 . Samples were incubated on ice for 10 min and then centrifuged at 5,000 rpm for 10 min, at 4°C, to remove potential proteins that may cause interference. Supernatant and washes of the resultant pellet with 30 % methanol were collected in amber glass vials and added to SPE cartridges.
SPE extractions were carried out in a cold room at 4°C. Cartridges were conditioned with 5 mL methanol followed by 5 mL Milli-Q water. After sample loading, cartridges were sequentially washed with 5 mL 15 % methanol (v/v), 5 mL Milli-Q water, and 2.5 mL hexane. Then, the sorbent phase was dried under a stream of nitrogen for 30 min, and the analytes were eluted using 2 mL methyl formate. The extraction procedure was performed using a vacuum manifold; the vacuum was adjusted so that individual drops could be seen from each cartridge. Extracts were evaporated to dryness under a fine stream of nitrogen; the residue was dissolved in 30 μL ethanol and stored at −80°C prior to LC-MS/MS analysis.
It is important to notice that during the sample spiking procedure, precursor fatty acids could be degraded rending hydroperoxy derivates. Also, impurities existing in the commercial standards of EPA, ARA, and DHA can become important since their addition level was huge in relation to the rest of the compounds. To avoid these potential problems, three sets of spiked samples were prepared in order to separately evaluate the recoveries of precursor fatty acids, hydroperoxy, and the rest of the analytes. Addition levels used in these sets of spiked samples were 150 ng/mL for PUFA metabolites, except for 12HEPE (600 ng/mL). Their precursors were added to plasma at much higher levels: EPA (3 μg/ mL), DHA (15 μg/mL), and ARA (45 μg/mL), which are in the same order of concentration as existing in nonspiked (blank) samples. The added concentration of IS (12HETE-d 8 ) was 500 ng/mL in all experiments.
Different recovery experiments were performed according to the step procedure where the compounds were spiked: at the beginning of the process (global recovery, SPE-LC-ESI-MS/ MS), after SPE (matrix effect, ESI-MS/MS), or comparing initial spiked samples with additions done after SPE (SPE recovery). The repeatability of the methodology was expressed as percentage of relative standard deviation (%RSD).
Apparatus
Analyses were carried out on two LC-MS systems. One system consists of two ProStar 210 high-pressure mixing pumps (Varian, Walnut Creek, CA, USA), a Metachem Technologies vacuum membrane degasser (Bath, UK), and an autosampler and thermostatted column compartment ProStar 410 module (Varian). This LC is coupled with a triple quadrupole 320-MS equipped with an electrospray interface (Varian). Nitrogen, used as a nebulizing and drying gas, is provided by a nitrogen generator (Domnick Hunter, Durham, UK). Argon (99.999 %) was used as collision gas. Instrument control and data acquisition were done by Varian MS Workstation software.
The other LC system consists of an Agilent 1260 Series (Agilent, Palo Alto, CA) that includes a binary pump, a degasser system, and a thermostatted autosampler, coupled to a LIT mass spectrometer LTQ Velos Pro equipped with an electrospray interface (Thermo Fisher, Rockford, IL, USA). Nitrogen was used as a nebulizing and drying gas and helium was used as the collision gas. Instrument control and data acquisition were done with Xcalibur software.
A Waters C18-Symmetry column, 150×2.1 mm, 3.5 μm (Milford, MA, USA), protected with a 4×2-mm C18 guard cartridge provided by Phenomenex (Torrance, CA, USA) was used to perform LC separations in both systems. SPE cleanup and extraction steps were performed using a vacuum manifold system from Supelco (Bellefonte, PA, USA) coupled to a vacuum pump from Millipore (Bedford, MA, USA). Plasma samples were foremost centrifuged in an Avanti J25 refrigerated centrifuge (Beckman Coulter, USA).
LC-MS/MS conditions
A binary eluent system of water (A) and methanol (B), both with 0.02 % (v/v) of formic acid, was used as the mobile phase in the LC separation. The gradient was as follows: 0-1 min (60 % B), 2-12 min (80 % B), 13-23 min (100 % B), and 25-30 min (60 % B). The flow rate was set to 0.2 mL/min, the column effluent was directly introduced in the ESI interface without splitting, and the injection volume was set to 10 μL. The column was maintained at room temperature, and the extracts were kept at −20°C right up to the injection moment. Retention times for target compounds are shown in Table 1 .
QqQ system
The ESI interface was operated in the negative mode with a needle potential of −4 kV, a source temperature of 50°C, a desolvation temperature of 200°C, a nebulizing gas pressure of 55 psi (380 kPa), and a drying gas pressure of 20 psi (138 kPa). Argon pressure in the collision cell was kept at 2 mTorr for MS/MS measurements. The mass window of the first and last quadrupoles was adjusted to 2.0 and 1.5 amu, respectively.
Selection of the most intense MS/MS transitions was done by direct infusion of individual standard solutions (5 μg/mL) at a flow rate of 20 μL/min. The intensity of the [M-H] − ion was optimized by varying the capillary voltage, and subsequently, the [M-H] − ion was subjected to MS/MS fragmentation experiments and the most intense product ions were obtained by varying the collision energy (0 to 60 eV) with the aid of the automated routines included in the software package. For each analyte, the two most intense or selective transitions were selected (Table 1) .
LITsystem
Operating conditions of the ESI source were negative ion mode with a sheath gas flow rate of 40 units, spray voltage of 5.5 kV, capillary temperature of 300°C and S-lens radiofrequency level of 60 %. The mass spectrometer was tuned optimizing voltages on the lenses and trap conditions while infusing standard solutions in the same way as the QqQ system. The collision-induced dissociation (CID) energy was optimized for each compound in order to maximize the intensity of their product ions. The identification of targeted compounds was helped with the full ion product spectra recorded in the range from 90 to 400m/z units. To quantify the analytes, the most intense and selective transition was used. Individual MS/ MS parameters for each compound are summarized in Table 1 . Table 1 summarizes the optimal MS/MS transitions selected for the QqQ and LIT assays. These transitions were recorded in order to facilitate the individual identification of the compounds minimizing further false positive identifications in biological samples. Once transitions were set, compounds were chromatographically separated on a C18 column using a gradient of water/methanol solvents with 0.02 % formic acid (v/v). Several compounds coeluted under the same chromatographic peak, but they could be individually quantified using specific transitions except for the particular case of the coeluting isomers PGE 3 and PGD 3 that also showed the same fragmentation pattern (Fig. S2 , Electronic Supplementary Material, presents their individual mass spectrum). MS 3 fragmentations tested for both prostaglandins in the LIT spectrometer did not provide further qualitative information; therefore, they were quantified together.
Results and discussion

Optimization of LC-ESI-MS/MS conditions
The LC separation cycle takes 30 min, including a 5-min column conditioning step before the next injection. Overall, this running time was comparable with other reported LC methods of eicosanoid analysis and provides the basis for a rapid assay [4, 38] . Some of the selected product ions for QqQ were in agreement with the available literature values as follows: TXB 3 367 > 169, 8iso-PGF 2α 353 > 192, PGE 2 351>271, 5HEPE 317>115, or 17HDoHE 343>281. However, for these compounds, the LIT transitions found were different than those previously reported. Transitions Figure 1 shows representative chromatograms of the analysis of these compounds.
Detection method validation Table 2 shows the values of linearity (from 1 to 500 ng/mL for oxidized derivates and 100 to 50,000 ng/mL for PUFAs), instrumental LODs and LOQs (defined for a signal to noise ratio of 3 and 10, respectively), and repeatability estimated by either of the two mass detectors. The standard calibration functions confirmed that both equipment achieved linear responses for all compounds, and R 2 ranged between 0.9860 and 0.9999. Acceptable precision was achieved by both instruments; RDSs % were lower than 12 % except for hydroperoxy compounds at 5 ng/mL level.
Finally, instrumental LODs and LOQs for the QqQ system were respectively estimated to be in the range of 0.003-7 and 0.01-23 ng/mL, and these values were in agreement with those previously reported in literature [3, 16, 24, 26, 28, 30, 39] . The LIT mass spectrometer achieved respectively LODs and LOQs between 0.002-3 and 0.006-10 ng/mL, values similar to those reported in a hybrid system consisting on a quadrupole ion trap mass analyzer (QTrap) operating in MRM mode [27] . No previous reports were found using a linear ion trap spectrometer operating in full scan product ion mode.
Optimization of solid-phase extraction (SPE)
Breakthrough and elution solvent volume, washing conditions, and extraction sorbent
In preliminary SPE experiments, aqueous samples (simulating plasma conditions) were used to optimize the SPE process trying two different cartridges, 60 mg Oasis-HLB and 100 mg C18. Methyl formate and ethanol were tested as eluting solvents achieving the same performance, even though methyl formate was selected due to its higher volatility that facilitates the later stage of concentration. Three consecutive 2 mL fractions of organic solvent were collected from SPE cartridges, previously spiked with 50 μL of a mixture solution of target compounds (200 ng/mL). Responses measured in the first fraction represented more than 98 % of the total for all compounds. Thus, 2 mL of methyl formate was the optimal eluting condition employed in further experiments. This extract was concentrated to dryness and finally reconstituted with 30 μL of ethanol. The breakthrough volume of both sorbents was investigated using up to 3 mL spiked aqueous samples passed through two cartridges connected in series (C18>C18 and HLB> HLB) and eluted separately. This sample volume, 3 mL, did not achieve the sorbent breakthrough volume due to none of the compounds were detected in the extract from the second cartridge, neither C18 nor HLB.
Considering biological and complex samples, many authors have demonstrated the importance of a washing sample step during the SPE procedure to reduce sample complexity and to prevent matrix effects during LC-ESI-MS determination. Washing conditions were set to 5 mL of water followed by 5 mL of 15 % methanol and 2.5 mL of hexane [16, 24, 26, 30] after verifying that none of the compounds were lost in the washing fraction.
Recoveries attained with Oasis-HLB and C18 cartridges were compared for 2 mL of spiked water samples at a final concentration of 150 ng/mL per compound. The comparative recovery results showed that HLB cartridges performed better than C18 ones for precursor fatty acids and hydroxy compounds, for which HLB recoveries ranged from 70 to 98 % while those were reduced to 42 to 82 % with the C18 sorbent (Fig. 2) . Eicosanoids, resolvins, and protectins were eluted with similar recoveries (70 to 105 %) in both sorbents (Fig. 2) , and they are in agreement with other published results using HLB [24, 25] and C18 [26, 27] . Hydroperoxy compound recoveries were higher using HLB sorbent than C18, but they still ranged from 50 to 70 %, so that further optimization of the process was required. On the basis of the results depicted in Fig. 2 , it was decided to select the HLB sorbent (never tested Table 2 Linearity (1 to 500 ng/mL for oxidized derivates and 100 to 50,000 ng/mL for PUFAs), limit of detection (LOD), limit of quantification (LOQ), and repeatability of LC-ESI/MS/MS assay at three concentration levels (5, 100, and 500 ng/mL) for target compounds for the QqQ and LIT mass spectrometers The repeatability of EPA, ARA, and DHA was determined at three different concentration levels: 100, 5,000, and 50,000 ng/mL (n=5)
for hydroxy and hydroperoxy metabolites) to continue with optimization of the extraction process.
Effect of sample pH, organic modifier addition, and temperature When the SPE conditions described in the above section for aqueous solutions were applied to plasma samples, a decrease in the yield of SPE process was noticed for all compounds. Thus, additional variables were evaluated in order to better understand the behavior of the analytes during the sample preparation process and, obviously, to improve the yield of sample preparation. Some authors have suggested that acidification of plasma to pH 3 before extraction improves the affinity of fatty acids and their derivatives by reversed-phase sorbents and, thus, the efficiency of SPE extraction [3, 40, 41] . However, we found similar efficiencies for acidified (pH 3) and nonacidified plasma samples (data not shown); thus, the pH of plasma was not modified.
The three fatty acids involved in this study (ARA, EPA, and DHA) and their hydroxy and hydroperoxy derivatives are relatively lipophilic compounds; thus, these compounds are more prone to be lost by lipophilic interactions with the pellet formed after sample centrifugation, and that could partially explain their low recoveries obtained. In order to verify this hypothesis, a series of experiments were performed by diluting spiked plasma samples (90 μL) with aqueous solutions (1 mL) containing different percentages of methanol from 0 to 50 %. After centrifugation, the supernatants were submitted to the SPE procedure and absolute recoveries calculated (Fig. 3) . In general, recoveries obtained for most compounds increased with the percentage of added methanol from 0 to 30 % (quantitative recoveries were achieved with 30 % of methanol). The exception to this trend corresponded to the free fatty acids (ARA, EPA, and DHA). Quantitative recoveries for these species were only achieved using 50 % of methanol, which is in agreement with their high octanol-water partition coefficients (K ow (ARA, 25°C) =6.99, K ow (EPA, 25°C) =6.50, K ow (DHA, 25°C) = 7.26). However, methanol proportions above 30 % reduced the 
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0% 15% 30% 50% Fig. 3 Comparative recovery results for the extraction with 60 mg HLB cartridges of spiked plasma samples (final concentration of 150 ng/mL per compound except for 12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL), and ARA (45 μg/mL)) supplemented with different percentages of methanol, 0 to 50 %, n=3 replicates 0   20   40   60   80   100   120   12HpEPE  15HpEPE  17HpDoHE  11HDoHE  11HETE  12HEPE  12HETEd8  15HEPE  17HDoHE  4HDoHE  5HEPE  LTB4  PD1  PGD3/PGE3  PGE2  RvD1  TXB3  8isoPGF2α  8isoPGF3a ARA EPA DHA
C18 HLB Fig. 2 Comparative SPE recovery results between 60 mg HLB and 100 mg C18 cartridges of 2 mL spiked water samples with a final concentration of 150 ng/mL per compound. The same extraction conditions were applied, at room temperature and neutral pH, n=3 replicates recovery for the more water-soluble species (eicosanoids, resolvins, and protectins) due to breakthrough problems in the cartridge. Thus, 30 % of methanol was the optimized organic modifier used to favor the extraction of minor metabolites of PUFAs in plasma. In the specific case of hydroperoxy compounds, the best recoveries were also obtained with 30 % of methanol.
The influence of the temperature during the extraction process was then checked comparing spiked plasma processed at room temperature and 4°C. Our results demonstrated that temperature had a critical impact on hydroperoxy compounds, while it did not affect the rest of the studied analytes (Fig. 4) . Hydroperoxy recoveries were around 50 % at room temperature, whereas such recoveries increased to 90-100 % at 4°C. Therefore, this is a critical parameter to be controlled in the global extraction process of lipid mediators.
To summarize, the optimal extraction conditions were set as follows: 90 μL of internal standard spiked plasma were 
Recovery at room temperature Recovery at 4º C Fig. 4 Comparative recovery results for the extraction with 60 mg HLB cartridges of spiked plasma samples (final concentration of 150 ng/mL to every compound except 12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL), and ARA (45 μg/mL)) doing the whole process at room temperature and 4°C, n=3 replicates 12HpEPE  13  11  27  88  91  99  29  88  15HpEPE  19  22  37  88  106  99  35  88  17HpDoHE  26  25  38  97  99  96  39  101  11HDoHE  5  5  97  94  100  118  97  80  11HETE  4  8  94  99 diluted with 1 mL 30 % methanol. After centrifugation, the supernatant was recovered and loaded into the barrel of an Oasis-HLB 60 mg SPE cartridge. The entire process was performed at 4°C. A scheme of optimized SPE method is provided as Electronic Supplementary Material in Fig. S3 .
Repeatability, SPE-LC-MS recoveries, and matrix effects Table 3 summarizes the repeatability of the entire optimized method, the overall recoveries for the SPE and SPE-LC-MS procedures, and the matrix effects for spiked plasma samples to a final concentration of 150 ng/mL per compound except for 12HEPE (600 ng/mL), EPA (3 μg/mL), DHA (15 μg/mL), and ARA (45 μg/mL), using 60 mg Oasis-HLB cartridges. Good and similar repeatabilities were obtained for the compounds using the two analyzers, with the exception of hydroperoxy analytes. Repeatabilities were ranged between RSD values of 1-15 % (13-26 % for hydroperoxy) by SPE-LC-ESI-QqQ and 3-13 % (11-25 % for hydroperoxy) by the SPE-LC-ESI-LIT system. Thus, the precision of the method is controlled by the sample preparation step rather than by the characteristics of the mass analyzer.
Global recoveries for LIT ranged from 80 to 112 % and were generally higher than QqQ global recoveries. In particular, the QqQ system provided global recoveries as low as 27-38 % for the three hydroperoxides (15HpEPE, 12HpEPE, and 17HpDoHE) and the hydroxyl 4HDoHE. Global recoveries for RvD 1 and PUFA precursors (ARA, EPA, and DHA) were also significantly lower, 50-71 %, with the QqQ configuration. SPE recoveries were around 100 % in both equipment with the exception of RvD 1 (67-75 %). Thus, according to the results compiled in Table 3 , the main parameter that affected the global recovery of analytes was the matrix effect.
It is known that the sensitivity and accuracy of the mass spectrometry determinations can be influenced by the coelution of matrix components with the ability to reduce or enhance the intensity of [M-H] − precursor ions. Matrix effects observed for the QqQ were higher than for the LIT. Seven compounds, i.e., the three hydroperoxides, 4HDoHE, and the three PUFA precursors, showed suppression of 28-71 % of their signal with the QqQ, while with the LIT system, only the precursors DHA and 11HDoHE exhibit matrix effect by losing their signal up to 29-20 %, respectively. There might be multiple reasons for the different matrix effects observed on the two systems. Ion suppression mainly occurs in the early stages of the ionization process; therefore, the difference in matrix effect contribution may be in part due to the particular design of the ESI source of each system [42] .
Application to plasma analysis
The optimized SPE-LC-MS/MS method was applied to plasma samples of genetically obese spontaneously hypertensive rats. Samples were analyzed by both instrumental systems and results were compared. As it has been assessed above, both equipment achieved similar quantitative performance in the analysis of standard compounds; however, the MRM acquisition mode (QqQ) gave several false identifications when it was applied to rat plasma samples. The QqQ system was not able to distinguish targeted compounds from other coeluting isomers with similar MRM transitions. It should be noted that oxygenated PUFA metabolites comprise an elevated number of isomeric and isobaric species that may coelute [23] . In contrast, the full ion product mode (LIT) provided full MS/ MS spectra which help to minimize the number of false positive identifications. As example, when plasma samples were analyzed by MRM mode, 11HDoHE was tentatively identified based on 343>121m/z quantification and 343> 149m/z identification transitions and on the retention time 18.33 and 18.25 min for the sample and standard solution (Fig. 5a, b) . However, the LIT MS/MS spectra obtained for the same peak revealed that its fragmentation pattern is different from the 11HDoHE standard (Fig. 5c, d ). This peak was probably a different coeluting hydroxy derivate of DHA, based on the typical fragments attributed to neutral losses of water (343>325 and 299>281m/z) and CO 2 (343>299) that were detected in both CID spectra. Different fragment ions from C-C cleavages were found (343>233, 255, and 161 in the sample and 343>194, 165, and 149 in the standard). There are at least other 14 bioactive lipids with the same exact mass than 11HDoHE (MW 344.235) [23] , that in the case of coelution may explain the observed false positive identification in plasma analysis. In a similar way, the full ion product mode confirmed the false positive identification of 15HEPE, 5HEPE, and 4HDoHE using the MRM mode. Quantitative results obtained with the LIT instrument are presented in Table 4 . Eight of the 23 searched compounds were identified. ARA was the metabolite found at the highest level (59,446 ng/mL) and TXB 3 was that present at the lowest concentration (3 ng/mL). Due to the concentration level of 17HpDoHE being higher than the maximum level of calibration, it was necessary to dilute the samples.
Conclusions
The present work describes the development of a robust and sensitive targeted analysis platform for the simultaneous quantification in blood plasma of a larger number of eicosanoids/ docosanoids (thromboxanes, prostaglandins, resolvins, protectins, leukotrienes, isoprostanes, hydroxy and hydroperoxy) which are quantified jointly to their PUFA precursors (ARA, EPA and DHA). The developed method overcame issues associated to the wide range of polarity (octanol-water partition coefficients ranged from 1.1 of PGD 3 to 7.3 of DHA), concentration (up to 4 orders of magnitude), and stability diversity (hydroperoxides are highly unstable) of these metabolites. Two mass detectors were tested: the most commonly used QqQ instrument operating in MRM and the LIT spectrometer working in full ion product scan mode. Although the QqQ assays were highly sensitive and selective and chromatographic separation was optimized, the full ion product scan acquisition on the LIT analyzer was more appropriated to minimize false positive identifications for these metabolites. The optimized methodology is simple, sensitive, and high-throughput and lends itself to lipidomic applications. The method can be used in biological applications targeted for biomarker discovery or other therapeutic and pharmacological approaches. It can be combined with information on metabolic, proteomic, and genomic profiles providing global evidence for evaluating the role of lipids at the cellular, tissue, and system levels. 
